Pfizer and the European Commission Enter into Manufacturing Reservation Agreement for mRNA-based Vaccines to Help Protect Against Future Pandemics

NEW YORK, June 30, 2023 — Pfizer Inc. (NYSE: PFE) announced today that it has entered into a manufacturing capacity reservation agreement with the European Health and Digital Executive Agency (HaDEA) of the European Commission (EC), which provides the European Union (EU) access to doses of a mRNA-based vaccine should one be developed to protect against a future pandemic-causing disease.

The agreement is focused on supporting the EU’s future pandemic preparedness. It ensures manufacturing capacity remains active to help close gaps between initial manufacturing and sufficient vaccine supply in the event of a public health emergency for the EU.

Building upon the company’s experience and leadership during the COVID-19 pandemic, Pfizer understands the urgent need for better pandemic preparedness and response planning and has taken several key steps towards readiness for potential future global disease outbreaks. Similar agreements have been reached previously between pharmaceutical manufacturers and countries globally to purchase flu and other vaccines.

Health equity is embedded in Pfizer’s corporate values, and Pfizer is committed to equitable access to vaccines. The company will continue to pursue similar agreements with other countries and multi-lateral organizations, building on the reliability and partnerships forged during the COVID-19 pandemic response.

Pfizer operates one of the largest global manufacturing networks and most sophisticated supply chains in innovative biopharma. Over its 174-year history, the company has built a global supply chain that can reallocate supplies quickly, across borders, to maintain supply and address shifting needs all over the world. Appropriate redundancies within Pfizer’s supply chain, such as extra inventory, increasing workers, and using multiple suppliers, help maintain resiliency.

About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com. In addition, to learn more, please visit us on and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Pfizer Disclosure Notice 
The information contained in this release is as of June 30, 2023. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, a manufacturing capacity reservation agreement between European Commission (EC) and Pfizer, Pfizer’s mRNA vaccine program and Pfizer’s manufacturing and supply chain capabilities, including their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that pre-clinical and clinical trial data are subject to differing interpretations and assessments; whether regulatory authorities will be satisfied with the design of and results from our pre-clinical and clinical studies; whether and when submissions to request emergency use or conditional marketing authorizations for any potential mRNA-based vaccine, and/or other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for any potential mRNA-based vaccine, and if obtained, whether or when such emergency use authorizations or licenses will expire or terminate; whether and when any such applications that may be pending or filed for any potential mRNA-based vaccine (including any requested amendments to the emergency use or conditional marketing authorizations) may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of such mRNA-based vaccine; the risk that we may not be able to maintain manufacturing capacity or access to logistics or supply channels commensurate with global demand for our vaccines, which would negatively impact our ability to supply our vaccines within the projected time periods; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

Pfizer:
Media Relations
+1 (212) 733-1226
[email protected]

Investor Relations
+1 (212) 733-4848
[email protected]

# # #